Theravance Biopharma Inc.
8.64
0.11 (1.29%)
At close: Jan 15, 2025, 3:59 PM
8.61
-0.35%
After-hours Jan 15, 2025, 04:00 PM EST
undefined%
Bid 8.35
Market Cap 424.87M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.03
PE Ratio (ttm) -8.39
Forward PE n/a
Analyst Buy
Ask 8.96
Volume 118,817
Avg. Volume (20D) 183,675
Open 8.67
Previous Close 8.53
Day's Range 8.61 - 8.86
52-Week Range 7.44 - 10.44
Beta undefined

About TBPH

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical tr...

[Show more]
Industry Biotechnology
Sector Healthcare
IPO Date May 16, 2014
Employees 99
Stock Exchange NASDAQ
Ticker Symbol TBPH
Website https://www.theravance.com

Analyst Forecast

According to 4 analyst ratings, the average rating for TBPH stock is "Buy." The 12-month stock price forecast is $12.5, which is an increase of 44.68% from the latest price.

Buy 50.00%
Hold 50.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Theravance Biopharma Inc. is scheduled to release its earnings on Feb 24, 2025, during market hours.
Analysts project revenue of $16.20M, reflecting a -7.77% YoY shrinking and earnings per share of -0.2, making a 17.65% increase YoY.

Why Price Moved

Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
2 months ago · Source
+8.64%
Theravance Biopharma shares are trading higher aft... Unlock content with Pro Subscription
5 months ago · Source
-18.35%
Theravance Biopharma shares are trading lower after the company reported mixed Q2 financial results. Also, Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $15 to $10.
news image

1 month ago · zacks.com

Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

news image

2 months ago · zacks.com

Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

news image

2 months ago · seekingalpha.com

Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Of...

news image

2 months ago · zacks.com

Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.01 per share a year ago.

news image

2 months ago · zacks.com

Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?

Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.

news image

2 months ago · zacks.com

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.

news image

2 months ago · zacks.com

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.

Create Price Alert on TBPH

Your price alert will notify you when the stock price is above 8.64.

Add to Watchlist